Henry Colecraft
Dr. Henry Colecraft is the John C. Dalton Professor of Physiology and Cellular Biophysics at Columbia and the inventor of engineered deubiquitinases, a breakthrough innovation that rescues proteins marked for destruction by many genetic diseases including cystic fibrosis, Long QT syndrome, and potentially many others. One of his startups, Stablix, launched with a $63M Series A financing from prominent venture capitalists. His second startup, Flux Therapeutics, raised $15M in seed funding led by Petrichor Healthcare Capital Management.